Let's talk

Dr Mei Chan

Senior Consultant

I am an epidemiologist, statistician, and actuary with a diverse background in population aging. At LCP, I work with the Health Analytics team to provide actionable insights to support healthcare and life science organizations facing complex health demands from aging populations. I help organizations translate cutting-edge research into practice, particularly through modeling health trajectories and analyzing health impacts using real-world data.

I received my PhD in Population Health from the University of Oxford, where I developed biological ages using novel high dimensional methods for disease risk prediction and communication. I have also worked in cross-industry, interdisciplinary research groups at University College London, analyzing health inequalities, multimorbidity trajectories and the effects of health interventions. Prior to and during my research career, I worked in several actuarial and statistical roles at Legal & General, specializing in longevity risk.

I am a member of steering groups and committees at the intersection of health research, statistics and the actuarial profession. These roles enable me to remain at the forefront of health research and modeling techniques, and to foster innovative interdisciplinary ways of working.

LCP have a practical way of looking at things and cut through the noise on essential issues.

LCP client

Featured insights

Breaking Waves

Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices

Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.

Read now

Yosemite National Park Waterfall

Reimagining patient support in the era of MFN: A strategic imperative for manufacturers

Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.

Read now

Rocky Mountain River

Achieving equitable representation in clinical trials

Matthew Hankins examines how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.

Read now

Redwood Forest

Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?

In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.

Listen now